Preclinical studies hypothesized that sPD-1 blocks the regulatory properties of PD-1/PD-L1, followed by restoration of T cell function, and proliferation and enhancement of immune-mediated tumor control [8]. The gene discussed is HOXD13; the disease is neoplasm.